Speakers 2024

Speakers 2022 2023 2024

Christophe FERRAND



Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft versus Leukemia, GvL), respectively. Based on the suicide gene therapy clinical trial (TKO), using ex-vivo Gene Modified T-cells (GMTC) and initiated in 2001 by our team, I have strongly contributed, as the scientific responsible, to bring the new suicide gene (iCASP9/AP1903) clinical trial Side by CIDe to the French regulatory agency (ANSM) approval (in the context of the new ATMP European regulations, ClinicalTrials.gov Identifier: NCT02849886)). Based on this experience in the field of T-cells, I have naturally redirected my research activity towards CART- cells immunotherapies by developing new approaches targeting original Tumor Associated Antigens expressed in Leukemia. With our team we made the proof of concept of an original idea of an anti-tumor immunotherapy based CART-cells in Acute Myeloid Leukemia (AML). Involvement in this gene therapy trial did allow me to a great experience in GMTC, their production and monitoring. A Phase I clinical trial will be the next step to bring this innovative medical drug to the patient With competences in immunology, vectorology (lenti or retrovirus), cell culture, gene therapy, suicide gene therapy, but also molecular biology in the field of Onco-Hematology, I have an interesting background in the field of Immunotherapies (CART-cells, TgTCR) that may be applied to hematology and other cancer treatment

Find also